

Integrin alpha4beta1 antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/IE42261E2ED4EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: IE42261E2ED4EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Integrin alpha4beta1 antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Integrin alpha4beta1 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Integrin alpha4beta1 antagonists Understanding

Integrin alpha4beta1 antagonists: Overview

Integrins are cell adhesion and signalling proteins crucial to a wide range of biological functions. Effective marketed treatments have successfully targeted integrins $\alpha 5 \beta 1$, $\alpha 4 \beta 1$ and $\alpha 2 \beta 1$ for cardiovascular diseases, inflammatory bowel disease/multiple sclerosis and dry eye disease, respectively. The related integrins $\alpha 4 \beta 7$ and $\alpha 4 \beta 1$ are therapeutic targets that are expressed on leukocytes and also recognize short peptide sequences, one of which is Leu-Asp-Val (LDV). There is some preclinical evidence that $\alpha 3 \beta 1$ (ref.82), $\alpha 4 \beta 1$ (ref.83) and $\alpha 8 \beta 1$ integrins play a role in pulmonary fibrosis, and that $\alpha v \beta 8$ is important in small airway fibrosis associated with chronic obstructive

pulmonary fibrosis and asthma.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Integrin alpha4beta1 antagonists R&D. The therapies under development are focused on novel approaches for Integrin alpha4beta1 antagonists.

Integrin alpha4beta1 antagonists Emerging Drugs Chapters

This segment of the Integrin alpha4beta1 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Integrin alpha4beta1 antagonists Emerging Drugs

Natalizumab: Biogen

Natalizumab is a monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis. It binds to the α 4-subunit of α 4b 1 and α 4b 7 integrins expressed on the surface of all leukocytes except neutrophils, and inhibits the α 4-mediated adhesion of leukocytes to their counter-receptor(s). Currently, it is being evaluated in phase II stage of development to treat Graft-versus-host disease.

AXR 159: AxeroVision

AXR-159 is being developed for the treatment of chronic Dry eyes disease (DED). AXR-270 is being developed for the short-term treatment of DED. Currently, it is in phase II stage of development to treat DED.

Further product details are provided in the report.....

Integrin alpha4beta1 antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Integrin alpha4beta1 antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Integrin alpha4beta1 antagonists

There are approx. 5+ key companies which are developing the Integrin alpha4beta1 antagonists. The companies which have their Integrin alpha4beta1 antagonists drug candidates in the most advanced stage, i.e. Phase II include, Biogen.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Integrin alpha4beta1 antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Integrin alpha4beta1 antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses Integrin alpha4beta1 antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Integrin alpha4beta1 antagonists drugs.

Integrin alpha4beta1 antagonists Report Insights

- Integrin alpha4beta1 antagonists Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Integrin alpha4beta1 antagonists Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Integrin alpha4beta1 antagonists drugs?

How many Integrin alpha4beta1 antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Integrin alpha4beta1 antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Integrin alpha4beta1 antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Integrin alpha4beta1 antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Biogen

AxeroVision

Polpharma Biologics

EA Pharma

BioMAS

Feramda

Key Products

Natalizumab

AXR-159

PB-006

AJM 300

AS 101

BIIB 107

SAS

Contents

- Introduction
- Executive Summary
- Integrin alpha4beta1 antagonists: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Integrin alpha4beta1 antagonists – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- PB-006: Polpharma Biologics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- AXR 159: AxeroVision
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis
- BIIB 107: Biogen
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products

Comparative Analysis
SAS: Feramda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Integrin alpha4beta1 antagonists Key Companies
Integrin alpha4beta1 antagonists Key Products
Integrin alpha4beta1 antagonists- Unmet Needs
Integrin alpha4beta1 antagonists- Market Drivers and Barriers
Integrin alpha4beta1 antagonists- Future Perspectives and Conclusion
Integrin alpha4beta1 antagonists Analyst Views
Integrin alpha4beta1 antagonists Key Companies
Appendix

I would like to order

Product name: Integrin alpha4beta1 antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/IE42261E2ED4EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IE42261E2ED4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970